Allergic Fungal Rhinosinusitis Diagnosis, Management, Associated Conditions, Pathophysiology, and Future Directions: Summary of a Multidisciplinary Workshop

Lauren T. Roland*, Cecelia Damask, Amber U. Luong, Antoine Azar, Charles S. Ebert, Thomas Edwards, Katherine N. Cahill, Do Yeon Cho, David Corry, Tara L. Croston, Alexandra F. Freeman, Amin Javer, Paneez Khoury, Jean Kim, Michael Koval, Edward D. McCoul, James W. Mims, Anju Peters, Jay F. Piccirillo, Richard P. RamonellAmali Samarasinghe, Robert P. Schleimer, Prestina Smith-Davidson, Andrej Spec, Michael E. Wechsler, Sarah K. Wise, Joshua M. Levy

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Allergic fungal rhinosinusitis (AFRS) is a unique endotype of chronic rhinosinusitis with nasal polyps (CRSwNP). Despite high recurrence rates and often more severe presenting signs compared with other subtypes of CRSwNP, research dedicated to AFRS has been lacking. Diagnostic criteria are outdated, the mechanistic relationship of AFRS to other associated diseases is unclear, and the pathophysiology of disease and risk factors for recurrence have not been well studied. In December 2023, a multidisciplinary group of rhinologists, otolaryngologists, pulmonologists, allergists, immunologists, scientists, and infectious disease experts met at the National Institute of Health to discuss unmet needs for future AFRS research and care, including patient management, diagnostic criteria, severity, pathophysiology, and related conditions. A summary of these clinical and associated research discussions is included below.

Original languageEnglish (US)
Pages (from-to)626-641
Number of pages16
JournalInternational Forum of Allergy and Rhinology
Volume15
Issue number6
DOIs
StateAccepted/In press - 2025

Funding

: This work was jointly supported by funds from the American Rhinologic Society (ARS), American Academy of Otolaryngic Allergy (AAOA) and NIDCD Division of Intramural Research to J.M.L. (DC000098\u201002). Funding We would like to acknowledge the participation of the following at the NIH Allergic Fungal Rhinosinusitis Workshop: Novartis, Sanofi, GSK, Regeneron, AstraZeneca, and Amgen. This work was jointly supported by funds from the American Rhinologic Society (ARS), American Academy of Otolaryngic Allergy (AAOA) and NIDCD Division of Intramural Research to J.M.L. (DC000098\u201002).

Keywords

  • allergic fungal sinusitis
  • allergic sinusitis
  • chronic rhinosinusitis
  • fungal sinusitis
  • invasive fungal sinusitis
  • nasal polyps

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'Allergic Fungal Rhinosinusitis Diagnosis, Management, Associated Conditions, Pathophysiology, and Future Directions: Summary of a Multidisciplinary Workshop'. Together they form a unique fingerprint.

Cite this